Michael Nassif is a Cardiology physician affiliated with Saint Luke's Health System. OpenAlex indexes 204 publications with 6,504 citations (h-index 38).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4330 Wornall Rd Ste 2000
Kansas City, MO 64111
Telephone
816-931-1883Registry record last updated 6 Jul 2018.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ENDOTRONIX, INC.Program year20241 payment
- ENDOTRONIX, INC.Program year20231 payment
- Abbott LaboratoriesProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
55.6%Beta blocker10.7%Carvedilol46%Metoprolol Succinate44%Metoprolol Tartrate11%Part D≥58 patientsStatin10.2%Atorvastatin Calcium59%Rosuvastatin Calcium41%Part D≥65 patients+ 17 more classes in this area
Metabolism & gastrointestinal
34.1%GLP-1 receptor agonist18.5%Ozempic55%Mounjaro36%Trulicity9%Part D≥94 patientsSGLT2 inhibitor8.5%Jardiance89%Farxiga11%Part D≥73 patients+ 6 more classes in this area
Blood & clotting
6.2%Factor Xa inhibitor3.7%Eliquis100%Part D≥33 patientsP2Y12 inhibitor1.7%Clopidogrel100%Part D≥18 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
New England Journal of Medicine
2025 - Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
New England Journal of Medicine
2024 - Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology
2024 - Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Suzanne Arnold, MD
Saint Luke's Health System
Carlos Bagley, MD
Saint Luke's Health System
Adam Salisbury, MD
Saint Luke's Health System
Ann Warner, MD
Saint Luke's Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”